Home Newsfeeds Raymond James Maintains Strong Buy on Aveanna Healthcare Hldgs, Lowers Price Target to $6

Raymond James Maintains Strong Buy on Aveanna Healthcare Hldgs, Lowers Price Target to $6

Raymond James analyst John Ransom maintains Aveanna Healthcare Hldgs (NASDAQ:AVAH) with a Strong Buy and lowers the price target from $8 to $6.

byBenzinga Newsdesk

August 15, 2022

1 minute read

Raymond James analyst John Ransom maintains Aveanna Healthcare Hldgs (NASDAQ:AVAH) with a Strong Buy and lowers the price target from $8 to $6.

Morgan Stanley Maintains Equal-Weight on Peloton Interactive, Lowers Price Target to $10

By Benzinga Newsdesk

August 26, 8:27 AM

Morgan Stanley analyst Lauren Schenk maintains Peloton Interactive (NASDAQ:PTON) with a Equal-Weight and lowers the price target from $19 to $10.

PTON

Twitter’s 2FA Shake-Up: Non-Blue Subscribers Out Of Luck, Google Authenticator To The Rescue

By Ananya Gairola

February 20, 2:25 PM

Not everyone is happy with Elon Musk‘s decision to force non-Twitter Blue subscribers to find another method instead…

AAPL

This Analyst Cuts Price Target On Snap? Here Are 5 Other Price Target Changes For Wednesday

By Lisa Levin

August 31, 7:42 AM

Citigroup cut the price target on Snap Inc. (NYSE: SNAP) from $16 to $10. Citigroup analyst Ronald Josey also downgraded the stock from Buy to Neutral. Snap shares fell 7% to $9.31 in pre-market trading.

AEO

News

Immunitybio Announces Results Of Anktiva Combined With Checkpoint Inhibitors In Non-Small Cell Lung Cancer; Schedules Meeting To Discuss Registration Path For ANKTIVA In Lung Cancer With FDA

By Benzinga Newsdesk

April 25, 2:57 AM

QUILT 3.055 trial completed and shows median overall survival almost double that of standard of care chemotherapy in 2nd- and 3rd-line non-small cell lung cancer (NSCLC) patients whose cancer did not respond to

IBRX

Raymond James Maintains Strong Buy on Aveanna Healthcare Hldgs, Lowers Price Target to $6

Related Posts

Morgan Stanley Maintains Equal-Weight on Peloton Interactive, Lowers Price Target to $10

Twitter’s 2FA Shake-Up: Non-Blue Subscribers Out Of Luck, Google Authenticator To The Rescue

This Analyst Cuts Price Target On Snap? Here Are 5 Other Price Target Changes For Wednesday

Immunitybio Announces Results Of Anktiva Combined With Checkpoint Inhibitors In Non-Small Cell Lung Cancer; Schedules Meeting To Discuss Registration Path For ANKTIVA In Lung Cancer With FDA